Ads
related to: chronic inflammatory demyelinating polyneuropathy treatments in adults- CIDP Treatment
Learn about the treatment process
and how to get started.
- CIDP Treatment Basics
Discover how treatment works and
what makes it unique.
- Disease Education Page
Learn more about the disease and
explore a glossary of common terms.
- Sign Up for Updates
Stay connected via email to get
relevant, helpful info sent to you.
- CIDP Treatment
Search results
Results From The WOW.Com Content Network
The disorder is sometimes called chronic relapsing polyneuropathy (CRP) or chronic inflammatory demyelinating polyradiculoneuropathy (because it involves the nerve roots). [2] CIDP is closely related to Guillain–Barré syndrome and it is considered the chronic counterpart of that acute disease. [ 3 ]
Efgartigimod alfa/hyaluronidase is indicated for the treatment of generalized myasthenia gravis in adults who are anti-acetylcholine receptor antibody positive. [1]In June 2024, the US Food and Drug Administration (FDA) expanded the indication for the combination to include the treatment of chronic inflammatory demyelinating polyneuropathy in adults.
Inflammatory demyelinating diseases (IDDs), sometimes called Idiopathic (IIDDs) due to the unknown etiology of some of them, are a heterogenous group of demyelinating diseases - conditions that cause damage to myelin, the protective sheath of nerve fibers - that occur against the background of an acute or chronic inflammatory process.
According to Lopate, et al., methylprednisolone is a viable treatment for chronic inflammatory demyelinative polyneuropathy (which can also be treated with intravenous immunoglobulin). The authors also indicate that prednisone has greater adverse effects in such treatment, as opposed to intermittent (high-doses) of the aforementioned medication.
The demyelinating diseases of the peripheral nervous system include: [citation needed] Guillain–Barré syndrome and its chronic counterpart, chronic inflammatory demyelinating polyneuropathy; Anti-MAG peripheral neuropathy; Charcot–Marie–Tooth disease and its counterpart Hereditary neuropathy with liability to pressure palsy
Efgartigimod alfa is also studied for the treatment of patients with chronic inflammatory demyelinating polyneuropathy (CIDP). The clinical trial known as ADHERE, conducted by Argenx, involved the enrollment of 322 individuals diagnosed with CIDP. [11] In the initial phase of the study, all subjects received weekly injections of Vyvgart.
Ads
related to: chronic inflammatory demyelinating polyneuropathy treatments in adults